ShankerValleau Wealth Advisors Inc. bought a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 2,088 shares of the company’s stock, valued at approximately $546,000. AbbVie accounts for approximately 0.1% of ShankerValleau Wealth Advisors Inc.’s portfolio, making the stock its 23rd largest holding.
A number of other large investors have also recently added to or reduced their stakes in ABBV. Corient Private Wealth LP acquired a new stake in shares of AbbVie in the 2nd quarter valued at about $559,736,000. Legal & General Group Plc bought a new stake in shares of AbbVie in the second quarter valued at about $2,905,952,000. Jupiter Topco LLC acquired a new position in shares of AbbVie during the second quarter worth about $1,560,354,000. Diamant Asset Management Inc. boosted its position in shares of AbbVie by 21,649.0% during the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock worth $798,456,000 after buying an additional 3,654,351 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in shares of AbbVie during the second quarter worth about $817,473,000. Institutional investors own 70.23% of the company’s stock.
AbbVie Trading Up 0.7%
Shares of ABBV stock opened at $285.32 on Friday. The firm’s fifty day moving average price is $262.74 and its two-hundred day moving average price is $239.22. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40. The firm has a market capitalization of $504.10 billion, a P/E ratio of 80.60, a PEG ratio of 1.30 and a beta of 0.24.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business posted $2.97 EPS. The company’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 13.94 EPS for the current fiscal year.
AbbVie Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s payout ratio is currently 195.48%.
Key Headlines Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
- Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
- Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
- Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
- Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
- Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on ABBV shares. BMO Capital Markets lifted their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Cantor Fitzgerald boosted their target price on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. HSBC upped their price target on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Rothschild & Co Redburn upped their price target on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, BNP Paribas Exane raised their price target on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $277.18.
View Our Latest Research Report on AbbVie
Insider Transactions at AbbVie
In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.
About AbbVie
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
Featured Articles
- Five stocks we like better than AbbVie
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
